海外の治験の状況「1」での検索結果
259件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Phase 1/2 Study to Evaluate the Safety and Efficacy of BMN 250 in Patients with MPS IIIB
- Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B, MPS IIIB) MedDRA version: 20.0 Level: LLT Classification code 10056918 Term: Sanfilippo's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.1 Level: PT Classification code 10056890 Term: Mucopolysaccharidosis III System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Australia, Colombia, Germany, Spain, Taiwan, Turkey, United Kingdom
- 2015-09-30
Authorised
- A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedCholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
- Subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocations, with other FGF/FGFR alterations, or who are negative for any FGF/FGFR alterations, who failed at least 1 previous treatment. MedDRA version: 19.1 Level: PT Classification code 10008593 Term: Cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, France, Germany, Israel, Italy, Korea, Republic of, Spain, Taiwan, Thailand, United Kingdom, United States
- 2017-03-21
Authorised
- Clinical Trial to investigate the bioavailability, safety and tolerability of Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizures
- refractory epilepsy with partial-onset seizures in children aged from 1 month to MedDRA version: 20.0 Level: LLT Classification code 10065336 Term: Partial epilepsy System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Croatia, Czech Republic, Italy, Portugal, Romania, Russian Federation, Serbia, Ukraine
- 2017-02-21
Authorised
- Clinical Trial to investigate the safety and tolerability of Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizures for one year
- refractory epilepsy with partial-onset seizures in children aged from 1 month to MedDRA version: 20.0 Level: LLT Classification code 10065336 Term: Partial epilepsy System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Croatia, Czech Republic, Italy, Portugal, Romania, Russian Federation, Serbia, Ukraine
- 2017-02-21
Authorised
- A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedCholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
- Subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocations, with other FGF/FGFR alterations, or who are negative for any FGF/FGFR alterations, who failed at least 1 previous treatment. MedDRA version: 20.0 Level: PT Classification code 10008593 Term: Cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium, France, Germany, Israel, Italy, Korea, Republic of, Spain, Taiwan, Thailand, United Kingdom, United States
- 2017-02-14
Authorised
- Safety and efficacy of fixed dose combination of Indapamide SR 1.5 mg / Amlodipine versus Valsartan / Amlodipine over 12-week of treatment in patients with uncontrolled essential hypertension after 1 month of treatment by Amlodipine 5 mg.
- Uncontrolled essential hypertension MedDRA version: 14.1 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Brazil, Bulgaria, Hungary, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, South Africa, Thailand, Turkey, Ukraine, United Kingdom, Vietnam
- 2013-04-09
Authorised
- Clinical Trial to investigate the bioavailability, safety and tolerability of Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizures
- refractory epilepsy with partial-onset seizures in children aged from 1 month to MedDRA version: 20.0 Level: LLT Classification code 10065336 Term: Partial epilepsy System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Croatia, Czech Republic, Italy, Portugal, Romania, Russian Federation, Serbia, Ukraine
- 2017-03-21
Authorised
- Clinical Trial to investigate the safety and tolerability of Eslicarbazepine Acetate as additive therapy in babies aged from 1 month to <2 years with refractory epilepsy with partial-onset seizures for one year
- refractory epilepsy with partial-onset seizures in children aged from 1 month to MedDRA version: 20.0 Level: LLT Classification code 10065336 Term: Partial epilepsy System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Croatia, Czech Republic, Italy, Portugal, Romania, Russian Federation, Serbia, Ukraine
- 2017-03-21
Authorised
- A Study of the Efficacy and Safety of Drug BAX 802 in Subjects with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures
- Congenital Haemophilia A with Factor VIII Inhibitors MedDRA version: 20.0 Level: LLT Classification code 10053751 Term: Hemophilia A with anti factor VIII System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Bulgaria, Canada, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, South Africa, Spain, Turkey, United Kingdom, United States
- 2016-03-15
Authorised
- To compare the efficacy of sulopenem IV followed by oral sulopenem-etzadroxil plus probenecid with ertapenem IV followed by oral ciprofloxacin or amoxicillin-clavulanate for the treatment of complicated urinary tract infection at Day 21 (± 1 day; test of cure [TOC visit]).
- Complicated urinary tract infection;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Poland, Russian Federation, Serbia, Slovakia, Ukraine, United States
- 2018-09-06